Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine–3;6–diamine is an experimental small molecule belonging to the aminoquinoline class of compounds[1]. It has a molecular formula of C19H18N4O2 and a molecular weight of approximately 334.37 g/mol[1][2][3]. The compound is not approved for any indication and has no known clinical use or marketed formulations as of June 2025[1][4]. It is referenced in chemical and biological databases (e.g., DrugBank DB06932; ChEMBL235157) as a kinase inhibitor with reported activity against the enzyme 3-phosphoinositide-dependent protein kinase 1 (PDPK1/PDK1), with an IC50 value around 60 nM in biochemical assays[1]. No further pharmacological or clinical data are available.
- Other names
- 10,11-Dimethoxy-4-methyldibenzo[c,f][2,7]naphthyridine-3,6-diamineDibenzo[c,f][2,7]naphthyridine-3,6-diamine, 10,11-dimethoxy-4-methyl-15,16-dimethoxy-6-methyl-8,12-diazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),2,4,6,8,11,13,15,17-nonaene-5,9-diamineCAS 936833–38–4
02
Targets
PDK (Pyruvate dehydrogenase kinase isoform 1)
Beyond the preview
Go deeper on 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine.